C18 synergi 4 μm fusion rp 80 lc column

STAT3 inhibitors - Stattic, cryptotanshinone, WP1066 and STA21 were obtained from Selleck Chemicals (Houston, TX, USA). TTI-101 was custom synthesized by Regis technologies Inc. (Morton Grove, IL, USA). Molecular grade dimethyl sulfoxide (DMSO), reduced glutathione (GSH), iodoacetamide, and N-ethylmaleimide were obtained from Sigma-Aldrich (St. Louis, MO, USA). Cisplatin was acquired from (TEVA Pharmaceuticals, North Wales, PA). All LC/MS reagents, including ammonium acetate, formic acid, acetonitrile, methanol and water, were obtained from Honeywell Fluka (Morris Plains, NJ, USA). STAT3 antibody was purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies to histone H2B (ab52484) and GAPDH (ab9485) were purchased from Abcam (Toronto, ON, Canada). Antibody to Vimentin (sc66002) was obtained from Santa Cruz Biotechnology (Dallas, TX, USA). DMEM XF base medium, FCCP, and rotenone/antimycin A were obtained from Agilent Technologies (Santa Clara, CA, USA). A C18 Synergi™ 4 μm Fusion-RP 80 Å LC column (50 × 2 mm) was purchased from Phenomenex, (Torrance, CA, USA); a Waters Symmetry C18 column (100 Å, 3.5 μm, 4.6 mm × 150 mm) was purchased from Waters (Milford, MA, USA).